ADC_Quick_Facts_Sheet

Addition of commercial-scale sterile injectables capabilities in Lexington, KY-Addition of development and commercial-scale capabilities in payload-linkers for bioconjugates in Riverview, MI-This is incremental to Piramal’s prior investments of $570 M in the US.

Stu Needleman, Chief Commercial Officer and Chief Patient Centricity Officer of Piramal Pharma Solutions, discusses the vision behind this expansion

$85M investment plan will add commercial scale sterile injectables capabilities. Expansion will significantly increase production capacity

Piramal Pharma Solutions' Aurora facility excels in the process/route selection, process development, and cGMP and non-GMP manufacturing of APIs. With extensive

On June 25, 2025, Piramal Pharma Solutions officially broke ground on a major expansion at our Sterile Injectable facility in Lexington, Kentucky.

$90M investment plan will add commercial scale sterile injectables capabilities. Expansion will significantly increase production capacity

Explore our global network of sites and capabilities designed to support your molecule from discovery through commercialization

ADCelerate is Piramal Pharma Solutions’ rapid approach to delivering Phase-I appropriate ADC drug substance and drug product

Explore our integrated ADC development and manufacturing services, designed to take your molecule from concept to clinic with speed and precision.

Generic Peptide APIs Peptides for Toxicology & Clinical Trials

Vaccines_and_Biologics_Quick_Facts_Sheet

We provide development and manufacturing of API and HPAPI across our facilities spread across North America, Europe and Asia 

Global Capabilities Sheet